Testing camrelizumab plus chemo and radiation before/after surgery for stomach-esophagus cancer
Part of Cancer, Digestive system clinical trials.
This trial tests combining the immunotherapy drug camrelizumab with chemotherapy and radiation before and after surgery for a specific type of stomach-esophagus cancer. It aims to see if this approach helps shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a type of cancer called gastroesophageal junction adenocarcinoma (Siewert II or III) that has not spread to other organs.
- Your cancer is considered resectable (can be removed by surgery) and is at a certain stage (T3-4N0M0 or T1-4N+M0).
- You have not had any prior cancer treatment (like surgery, chemo, or radiation) for this condition.
- You are in good general health, able to do daily activities without much help (ECOG 0 or 1), and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving the immunotherapy drug camrelizumab together with chemotherapy before surgery can help people with esophageal cancer avoid needing full removal of the esophagus. It aims to preserve the esophagus while still treating the cancer effectively.
This trial tests whether giving immunotherapy (a treatment that helps your immune system fight cancer) along with chemotherapy and radiation before surgery can help shrink tumors in people with stomach cancer at the esophagus-stomach junction. The goal is to see if this approach is safe and effective before the main surgery.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This trial tests giving an immunotherapy drug (adebrelimab) along with two chemotherapy drugs (capecitabine and oxaliplatin) before and after surgery for a specific type of stomach-cancer junction tumor. It aims to see if this combination is safe and effective in shrinking the tumor and improving outcomes.
This trial tests whether adding a targeted radiation treatment during surgery to the usual combination of immunotherapy and chemotherapy helps people with advanced stomach cancer before they have surgery to remove the tumor. The goal is to see if this extra treatment can improve outcomes.
This trial tests a combination of chemotherapy (FLOT), an immunotherapy drug (pembrolizumab), and short-course radiation before surgery for gastroesophageal junction cancer. The goal is to see if this approach improves outcomes.
Hear when a new Gastroesophageal Junction Adenocarcinoma (Siewert II-III) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.